Interpreting HIV Laboratory Results
CD4 cell count, HIV-1 RNA viral load, and resistance testing are the three essential parameters that together define disease stage, guide treatment decisions, and monitor therapeutic response in HIV-positive patients.
Core Laboratory Parameters
CD4 Cell Count
The CD4 count serves as the primary marker of immune function and disease stage:
- Above 500 cells/mm³: Indicates preserved immune function
- 350-500 cells/mm³: Moderate immunodeficiency; treatment generally recommended 1
- 200-350 cells/mm³: Significant immunodeficiency; treatment strongly indicated
- Below 200 cells/mm³: Severe immunodeficiency (AIDS-defining); urgent treatment required and opportunistic infection prophylaxis needed 1
Important caveat: CD4 counts fluctuate naturally—a decline greater than 30% from baseline for absolute numbers or greater than 3% for percentages is considered clinically significant 2. Always confirm concerning values with repeat testing.
HIV-1 RNA Viral Load (Plasma Viremia)
Viral load is the single best predictor of disease progression and the key parameter for evaluating treatment response 1, 3, 4. The prognostic categories are:
- ≤500 copies/mL: Minimal risk of progression
- 501-3,000 copies/mL: Low risk (16.6% progression to AIDS within 6 years)
- 3,001-10,000 copies/mL: Moderate risk (31.7% progression within 6 years)
- 10,001-30,000 copies/mL: High risk (55.2% progression within 6 years)
- >30,000 copies/mL: Very high risk (80% progression to AIDS within 6 years) 4
Viral load above 55,000 copies/mL is a strong indication for treatment initiation regardless of CD4 count 1.
Resistance Testing
Genotypic resistance testing (reverse transcriptase-protease genotype) should be obtained at HIV diagnosis before starting therapy to maximize the number of active drugs in the initial regimen 1, 3, 5. Integrase resistance testing is not routinely needed unless the patient previously took cabotegravir-containing PrEP or acquired HIV from a partner with known integrase resistance 5.
Combined Interpretation Algorithm
The prognosis is most accurately defined by combining both viral load and CD4 count 4:
- High CD4 (>350) + Low viral load (<10,000): Lowest risk; may defer treatment in asymptomatic patients, though current guidelines favor earlier treatment
- High CD4 (>350) + High viral load (>55,000): Treatment recommended despite preserved immune function 1
- Low CD4 (<350) + Any viral load: Treatment strongly indicated
- Low CD4 (<200) + High viral load (>5,000): Highest risk category; urgent treatment initiation required 6
Critical point: Viral load strongly predicts the rate of CD4 decline. A patient with viral load >100,000 copies/mL will progress much faster than one with <10,000 copies/mL, even at the same CD4 count 4, 7.
Monitoring During Treatment
Expected Response Timeline
After starting antiretroviral therapy 1, 3, 1:
- 4-8 weeks: Expect 0.5-0.75 log₁₀ (3-5 fold) reduction in viral load
- 12-16 weeks: Viral load should be undetectable (<50 copies/mL)
- 4-6 months: Goal is undetectable viral load (<50 copies/mL) with rising CD4 count
Monitoring Frequency
Most recent guidelines recommend 5, 8:
- Viral load: At 4-6 weeks after starting ART, then every 3 months for the first year, then every 6 months if consistently suppressed
- CD4 count: At baseline, then can be monitored annually once viral suppression is achieved and CD4 is >350 cells/mm³ 5, 8
Important update: Quarterly CD4 monitoring in stable, virologically suppressed patients has minimal clinical utility—the probability of CD4 dropping below 350 cells/mm³ is less than 2% when viral load remains suppressed 9.
Red Flags Requiring Action
Treatment Failure Indicators 1, 3, 1
- Less than 1 log₁₀ reduction in viral load by 8 weeks
- Failure to achieve undetectable viral load (<50 copies/mL) by 6 months
- Detectable virus after initial suppression (virologic rebound)
- Any confirmed 3-fold increase in viral load from nadir
- Persistent CD4 decline on two occasions despite treatment
When viral load becomes detectable after suppression: If the increase is modest (50-5,000 copies/mL), close observation is reasonable initially, but most patients will show progressive increases requiring regimen change 1. Assess adherence first, then consider resistance testing if adherence is adequate.
Discordant Results
When CD4 and viral load trends diverge (occurs in ~20% of patients) 2:
- Viral load takes priority for treatment decisions
- Rising viral load with stable CD4 indicates treatment failure
- Falling CD4 with suppressed viral load may not require immediate regimen change but warrants close monitoring
- Consider expert consultation for complex discordant cases
Additional Baseline Testing
Before starting treatment 5:
- Hepatitis A, B, and C screening
- Sexually transmitted infection testing
- Tuberculosis screening
- Cryptococcal antigen if CD4 <100 cells/mm³
- Pregnancy test in persons of childbearing potential
- Baseline metabolic panel, lipids, kidney and liver function
Do not delay treatment initiation while waiting for these results—start ART immediately and follow up results subsequently 5.